CMS advises biotechnology firm Tubulis on EUR 60 million Series B financing round

Munich – Biotech company Tubulis has successfully completed a Series B round of financing worth EUR 60 million. Three new investors, Andera Partners, Evotec SE and Fund+, joined the round. All the existing investors, including Bayern Kapital, BioMedPartners, coparion, High-Tech Gründerfonds and Seventure Partners, also took part in this Series B financing round. The new capital will be used to advance Tubulis’ proprietary pipeline of antibody drug conjugates (ADCs) towards clinical evaluation as well as to introduce programmes addressing a range of solid tumour indications. The proceeds will also enable the company to deliver the therapeutic potential of ADCs through innovation of novel payload classes and identification of new cancer targets.

A CMS team headed by lead partner Stefan-Ulrich Müller advised Tubulis on all legal aspects of the round of financing. The team headed by the Munich-based CMS partner has been advising the biotech firm for some years on a wide range of legal areas.

CMS Germany

Stefan-Ulrich Müller, Lead Partner, Munich
Sebastian Hummel, Associate, Munich
Matthias Unger, Associate, Munich, all Corporate/Venture Capital
Stefan Lüft, Partner, Munich
Annika Lindemann, Senior Associate, Munich, both Intellectual Property
Stefan Lehr, Partner, Frankfurt/Main, Competition & EU
Dr Benedikt Forschner, Counsel, Munich, Labor, Employment & Pensions

Press Contact
presse@cms-hs.com